相关实验视频

Updated: Jul 11, 2026

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Dynamic Lung Tumor Tracking for Stereotactic Ablative Body Radiation Therapy

Published on: June 7, 2015

对PSMA-PET/CT分阶段,小转移性前列腺癌的立体离体放射疗法 - 一项多中心研究

Isabelle Schupak¹, Michael Chao², Mario Guerrieri³

¹GenesisCare, St Vincent's Hospital, Basement Level Building, C/41 Victoria Parade, Fitzroy, Victoria 3065, Australia; Olivia Newton-John Cancer Wellness & Research Centre (Austin Health), 145 Studley Road, Heidelberg, Victoria 3084, Australia.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

|October 25, 2025

概括

针对小卵性前列腺癌 (omPC) 的立体除体放射疗法 (SABR) 显示出延迟治疗升级的前景. 这项研究发现,SABR有效地管理了omPC,延迟了三年后的雄激素剥夺疗法 (ADT) 暴露.

科学领域:

在瘤学瘤学.
辐射瘤学辐射瘤学
尿道瘤学尿道瘤学

背景情况:

低甲状腺性前列腺癌 (OMPC) 越来越多地通过转移导向治疗来管理.
立体除性体辐射疗法 (SABR) 正在成为OMPC的关键治疗方式.
从缓解性雄激素剥夺疗法 (ADT) 转向转移导向疗法,需要评估SABR的疗效.

研究的目的:

评估OMPC患者用SABR治疗的生物化学和临床结果.
评估SABR在延迟治疗升级和ADT启动方面的有效性.
报告一组OMPC患者的生存终点,分期使用PSMA-PET/CT.

主要方法:

在2015-2019年期间,对213名OMPC患者进行了SABR治疗的回顾性多中心病例系列.
患者使用PSMA-PET/CT进行分期;同时允许ADT.
主要终点:无生物化学失败生存率 (BCFFS);次要终点包括无临床失败生存率 (CFFS) 和无ADT生存率 (ADT-FS).

主要成果:

36个月后的BCFFS为18.8%,36个月后的CFFS为39.2%.
无ADT的中位数生存时间为41.98个月,无ADT的5年生存时间为37.5%.
SABR被输送到骨 (41.3%) 和结节 (49.3%) 的转移.

结论:

这项研究代表了用SABR治疗的PSMA PET阶段omPC患者中最大的队列.
在OMPC患者中,SABR有效延迟治疗升级和ADT暴露超过三年.
SABR显示出作为OMPC转移导向治疗的显著潜力.

关键词:

没有ADT的生存率 (ADT-FS)没有生化失败的生存率 (BCFFS)没有临床失败的生存率 (CFFS)转移导向疗法 (MDT) 是一种转移导向疗法.低基质性前列腺癌 (OMPC) 是一种前列腺癌.PSMA PET/CT分阶段进行.立体性除性身体辐射疗法 (SABR)

更多相关视频

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

相关概念视频

Positron Emission Tomography

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body being...

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Imaging Studies II: Positron Emission Tomography and Scintigraphy

Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET